{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:57:22Z","timestamp":1762275442062,"version":"build-2065373602"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Public Health Pol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1057\/s41271-025-00598-2","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:12:26Z","timestamp":1761351146000},"page":"916-924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges of high-quality clinical research in Colombia: an example of a clinical trial amidst the COVID-19 pandemic"],"prefix":"10.1057","volume":"46","author":[{"given":"Alonso","family":"Vera-Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-6190","authenticated-orcid":false,"given":"Nicolas A.","family":"Cortes-Mejia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"de la Hoz-Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Fernanda","family":"Bejarano-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"598_CR1","unstructured":"Organization, W.H. Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection is Suspected. 2021 https:\/\/iris.who.int\/bitstream\/handle\/10665\/349321\/WHO-2019-nCoV-clinical-2021.2-eng.pdf?sequence=1."},{"issue":"3","key":"598_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jmii.2020.04.003","volume":"53","author":"MY Yen","year":"2020","unstructured":"Yen MY, et al. Recommendations for protecting against and mitigating the COVID-19 pandemic in long-term care facilities. J Microbiol Immunol Infect. 2020;53(3):447\u201353.","journal-title":"J Microbiol Immunol Infect"},{"key":"598_CR3","unstructured":"Organization, W.H. Living Guidance for clinical management of COVID-19. 2021."},{"issue":"4","key":"598_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/jmcb\/mjaa014","volume":"12","author":"M Huang","year":"2020","unstructured":"Huang M, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol. 2020;12(4):322\u20135.","journal-title":"J Mol Cell Biol"},{"issue":"19","key":"598_CR5","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787\u201399.","journal-title":"N Engl J Med"},{"issue":"8","key":"598_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RC Group","year":"2021","unstructured":"Group RC, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704.","journal-title":"N Engl J Med"},{"issue":"20","key":"598_CR7","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu X, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"598_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1741-7015-11-166","volume":"11","author":"AJ Boyle","year":"2013","unstructured":"Boyle AJ, Sweeney RM, McAuley DF. Pharmacological treatments in ARDS; a state-of-the-art update. BMC Med. 2013;11(1):166.","journal-title":"BMC Med"},{"issue":"3","key":"598_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccc.2011.05.001","volume":"27","author":"N Puri","year":"2011","unstructured":"Puri N, Dellinger R. Inhaled nitric oxide and inhaled prostacyclin in acute respiratory distress syndrome: what is the evidence? Crit Care Clin. 2011;27(3):561\u201387.","journal-title":"Crit Care Clin"},{"issue":"02","key":"598_CR10","first-page":"53","volume":"5","author":"V Samuel","year":"2020","unstructured":"Samuel V, et al. The use of intravenous prostaglandins in extremity ischemia. Int J Recent Surg Med Sci. 2020;5(02):53\u20137.","journal-title":"Int J Recent Surg Med Sci"},{"issue":"8","key":"598_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1482","volume":"6","author":"M Nomali","year":"2023","unstructured":"Nomali M, et al. Challenges and solutions in clinical research during the COVID-19 pandemic: a narrative review. Health Sci Rep. 2023;6(8):e1482.","journal-title":"Health Sci Rep"},{"key":"598_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/B978-0-12-381537-8.10014-7","volume-title":"Global clinical trials","author":"H Ukwu","year":"2011","unstructured":"Ukwu H, et al. Chapter 14 - clinical trials in Latin America. In: Chin R, Bairu M, editors., et al., Global clinical trials. San Diego: Academic Press; 2011. p. 271\u2013308."},{"key":"598_CR13","doi-asserted-by":"publisher","DOI":"10.1590\/s1678-4634202046221628","volume":"46","author":"DLD Souza","year":"2020","unstructured":"Souza DLD, et al. A perspectiva dos pesquisadores sobre os desafios da pesquisa no Brasil. Educa\u00e7\u00e3o e Pesquisa. 2020;46:e221628.","journal-title":"Educa\u00e7\u00e3o e Pesquisa"},{"issue":"6","key":"598_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s12192-017-0815-8","volume":"22","author":"DR Ciocca","year":"2017","unstructured":"Ciocca DR, Delgado G. The reality of scientific research in Latin America; an insider\u2019s perspective. Cell Stress Chaperones. 2017;22(6):847\u201352.","journal-title":"Cell Stress Chaperones"},{"key":"598_CR15","first-page":"401","volume":"29","author":"DIMd Salazar","year":"2022","unstructured":"Salazar DIMd, Salazar-Espinosa JF. Investigaci\u00f3n cl\u00ednica en Latinoam\u00e9rica y Colombia durante la pandemia por COVID-19. Rev Colomb Cardiol. 2022;29:401\u20133.","journal-title":"Rev Colomb Cardiol"},{"key":"598_CR16","unstructured":"Gobierno de, C., Misi\u00f3n de Sabios Colombia - 2019. Bogot\u00e1: Gobierno de Colombia; 2019."},{"issue":"2","key":"598_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4067\/S0034-98872021000100110","volume":"149","author":"B Aguilera","year":"2021","unstructured":"Aguilera B. Trends in clinical trials performed in Chile. Rev Med Chil. 2021;149(2):110\u20138.","journal-title":"Rev Med Chil"},{"issue":"5","key":"598_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1590\/S1020-49892011001100007","volume":"30","author":"L White","year":"2011","unstructured":"White L, et al. Clinical trial regulation in Argentina: overview and analysis of regulatory framework, use of existing tools, and researchers\u2019 perspectives to identify potential barriers. Rev Panam Salud Publica. 2011;30(5):445\u201352.","journal-title":"Rev Panam Salud Publica"},{"issue":"2","key":"598_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/pad.1824","volume":"38","author":"R Peeters","year":"2018","unstructured":"Peeters R, et al. Low-trust bureaucracy: understanding the Mexican bureaucratic experience. Public Adm Dev. 2018;38(2):65\u201374.","journal-title":"Public Adm Dev"},{"issue":"6","key":"598_CR20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s43441-023-00565-7","volume":"57","author":"U Argotti","year":"2023","unstructured":"Argotti U, et al. Comparison of the Latin America regulation landscape and international reference health authorities to hasten drug registration and clinical research applications. Ther Innov Regul Sci. 2023;57(6):1287\u201397.","journal-title":"Ther Innov Regul Sci"},{"key":"598_CR21","unstructured":"Ochoa, Tiempos de respuesta regulatoria para ensayos cl\u00ednicos en ocasiones superan los 10 meses afectando competitividad del pa\u00eds. Novedades cientificas, comunicados. 2024. https:\/\/afidro.org\/2024\/06\/24\/solo-el-55-de-los-ensayos-clinicos-en-colombia-son-aprobados-por-el-invima\/#_ftnref2."},{"key":"598_CR22","unstructured":"Ministerio de la Protecci\u00f3n, S., Resoluci\u00f3n N\u00famero 2378 de 2008: Por la cual se adoptan las Buenas Pr\u00e1cticas Cl\u00ednicas para las instituciones que conducen investigaci\u00f3n con medicamentos en seres humanos. Ministerio de la Protecci\u00f3n Social; 2008."},{"key":"598_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.18601\/01236458.n61.08","volume":"61","author":"J Escobar-Triana","year":"2025","unstructured":"Escobar-Triana J, et al. Comit\u00e9s de \u00c9tica en investigaci\u00f3n con seres humanos en Colombia: evoluci\u00f3n, experiencias y desaf\u00edos. Con-texto. 2025;61:159\u201374.","journal-title":"Con-texto"},{"key":"598_CR24","unstructured":"Ministerio de Ciencia, T.e.I.d.C., Pol\u00edtica Nacional de \u00c9tica en Ciencia, Tecnolog\u00eda e Innovaci\u00f3n. 2020."},{"key":"598_CR25","unstructured":"Institute of Medicine Forum on Drug Discovery, D. and Translation, Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary.Washington: National Academies Press (US); 2010."},{"key":"598_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00961","volume":"8","author":"RE da Silva","year":"2017","unstructured":"da Silva RE, et al. International clinical trials in Latin American and Caribbean countries: research and development to meet local health needs. Front Pharmacol. 2017;8:961.","journal-title":"Front Pharmacol"},{"key":"598_CR27","unstructured":"Research!America, Investment in Research: A Report from Research!America. Alexandria: Research!America; 2022."},{"issue":"11","key":"598_CR28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/pds.4989","volume":"29","author":"M Salas","year":"2020","unstructured":"Salas M, et al. Challenges facing drug utilization research in the Latin American region. Pharmacoepidemiol Drug Saf. 2020;29(11):1353\u201363.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"598_CR29","unstructured":"Organisation for Economic, C.-O. and Development, Gross Domestic Spending on R&D. 2023."},{"key":"598_CR30","volume-title":"The economics of knowledge","author":"D Foray","year":"2006","unstructured":"Foray D. The economics of knowledge, vol. 1. Cambridge: MIT Press; 2006."},{"issue":"3","key":"598_CR31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/pds.5404","volume":"31","author":"LC Lopes","year":"2022","unstructured":"Lopes LC, et al. Data sources for drug utilization research in Latin American countries-a cross-national study: DASDUR-LATAM study. Pharmacoepidemiol Drug Saf. 2022;31(3):343\u201352.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"598_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1590\/S0124-00642009000200014","volume":"11","author":"CA Agudelo","year":"2009","unstructured":"Agudelo CA, et al. Prioridades de Investigaci\u00f3n en Salud en Colombia: Perspectiva de los Investigadores. Revista de Salud P\u00fablica. 2009;11(2):301.","journal-title":"Revista de Salud P\u00fablica"},{"issue":"3","key":"598_CR33","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1097\/SLA.0000000000004114","volume":"272","author":"JD Beane","year":"2020","unstructured":"Beane JD, et al. Conducting clinical trials in the time of a pandemic. Ann Surg. 2020;272(3):e219\u201321.","journal-title":"Ann Surg"},{"key":"598_CR34","unstructured":"Priscila, F. and M. Ana Elisa, Regulatory Focus: Brazil - June 2018. 2018."},{"key":"598_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.768376","volume":"8","author":"H Rodriguez","year":"2021","unstructured":"Rodriguez H, De Lucia ML. A proposal of a combined convergence regulatory strategy applied to post-approval changes by Latin American countries, reducing workload and allowing continuous improvement to guarantee the quality, safety, and efficacy of medicines. Front Med (Lausanne). 2021;8:768376.","journal-title":"Front Med (Lausanne)"},{"issue":"67","key":"598_CR36","first-page":"220","volume":"17","author":"IM Bignone","year":"2006","unstructured":"Bignone IM. Issues regarding the legal regulation of drugs in Argentina. Vertex. 2006;17(67):220\u20133.","journal-title":"Vertex"}],"container-title":["Journal of Public Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1057\/s41271-025-00598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1057\/s41271-025-00598-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1057\/s41271-025-00598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:52:37Z","timestamp":1762275157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1057\/s41271-025-00598-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1057\/s41271-025-00598-2","relation":{},"ISSN":["0197-5897","1745-655X"],"issn-type":[{"type":"print","value":"0197-5897"},{"type":"electronic","value":"1745-655X"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}